Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease

doi:10.3748/wjg.v31.i47.114651

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 47

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (606)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

208

Figures (1-4)

Tables (1-3)

Sum=300

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

208

Sum=253

Dec 21, 2025 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Dec 21, 2025; 31(47): 114651
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114651

Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease

Gabriel Heymann, Saumik Rahman, Daniel Kats, Bubu A Banini, Srinivas Gaddam, Elise Aslanian, Sarpong Boateng, Gary Israel, Thiruvengadam Muniraj

Gabriel Heymann, Sarpong Boateng, Department of Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT 06606, United States

Saumik Rahman, Gary Israel, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, United States

Daniel Kats, Department of Medicine, Brown University, Providence, RI 02912, United States

Bubu A Banini, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States

Srinivas Gaddam, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

Elise Aslanian, Section of Digestive Disease, Yale School of Medicine, New Haven, CT 06510, United States

Thiruvengadam Muniraj, Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, United States

Author contributions: Muniraj T and Heymann G had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis; Heymann G, Rahman S, Kats S, Banini BA, Gaddam S, Aslanian H, Boateng S, Israel G, and Muniraj T are responsible for the study concept and design, acquisition of data, analysis and interpretation of data and drafting of the manuscript.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Yale University.

Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Data sharing statement: No additional data are available.

Corresponding author: Thiruvengadam Muniraj, MD, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520, United States. thiruvengadam.muniraj@yale.edu

Received: September 26, 2025
Revised: October 19, 2025
Accepted: November 3, 2025
Published online: December 21, 2025
Processing time: 85 Days and 23.8 Hours

Core Tip

Core Tip: Non-alcoholic fatty pancreas disease (NAFPD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are commonly co-occurring disorders associated with metabolic dysregulation with important clinical implications. Few studies have examined the relationship between these conditions in terms of disease severity. We perform a retrospective analysis of patients with biopsy-proven MASLD, and non-contrast enhanced abdominal computed tomography to assess how NAFPD correlates with degrees of hepatic steatosis, steatohepatitis, and hepatic fibrosis. We find that most patients with MASLD met criteria for NAFPD, but the degree of pancreatic steatosis did not portend a greater degree of hepatic steatosis, steatohepatitis, or hepatic fibrosis.